Is BYD a Threat To Tesla Shareholders?
BYD (OTC:BYDDY) has rocketed to the top of China’s booming…
Buy
73
CLOV Quote, Financials, Valuation and Earnings
Last price:
$3.85
Seasonality move
:
50.4%
Day range:
$3.40 - $3.90
52-week range:
$0.79 - $4.87
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.41x
P/B ratio:
5.65x
Volume:
12.9M
Avg. volume:
5.7M
1-year change:
409.46%
Market cap:
$1.9B
Revenue:
$1.4B
EPS (TTM):
-$0.09
Analysts' Opinion
-
Consensus RatingClover Health Investments has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $4.69, Clover Health Investments has an estimated upside of 26% from its current price of $3.77.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $3.75 representing 0.53% downside risk from its current price of $3.77.
Fair Value
-
According to the consensus of 4 analysts, Clover Health Investments has 26% upside to fair value with a price target of $4.69 per share.
CLOV vs. S&P 500
-
Over the past 5 trading days, Clover Health Investments has overperformed the S&P 500 by 11.97% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Clover Health Investments does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Clover Health Investments has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Clover Health Investments reported revenues of $337M.
Earnings Growth
-
Clover Health Investments has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Clover Health Investments reported earnings per share of -$0.04.
Enterprise value:
1.7B
EV / Invested capital:
--
Price / LTM sales:
1.41x
EV / EBIT:
--
EV / Revenue:
1.24x
PEG ratio (5yr expected):
--
EV / Free cash flow:
51.21x
Price / Operating cash flow:
57.97x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$364.8M
Return On Assets:
-6.83%
Net Income Margin (TTM):
-3.14%
Return On Equity:
-13.55%
Return On Invested Capital:
-13.55%
Operating Margin:
-6.37%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $1.1B | $1.3B | $1.4B | $312.4M | $337M | |
| Gross Profit | $103.5M | $256M | $364.8M | $62.6M | $93.9M | |
| Operating Income | -$286.7M | -$179.6M | -$45.5M | -$45.2M | -$21.4M | |
| EBITDA | -$252M | -$205.8M | -$44.1M | -$67.3M | -$21.1M | |
| Diluted EPS | -$0.72 | -$0.46 | -$0.09 | -$0.15 | -$0.04 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $189.8M | $752.5M | $625M | $428M | $343.1M | |
| Total Assets | $267.3M | $950.8M | $808.6M | $570.7M | $580.7M | |
| Current Liabilities | $164.2M | $372.6M | $431.5M | $261.1M | $213.5M | |
| Total Liabilities | $880.4M | $411.5M | $451.7M | $284.3M | $239.6M | |
| Total Equity | -$613.2M | $539.3M | $356.9M | $286.4M | $341.1M | |
| Total Debt | $127.2M | $19.9M | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$203.9M | -$144.7M | $34.8M | -$258.1M | -$85.8M | |
| Cash From Investing | $95.1M | $140M | $565K | $83.7M | -$1.4M | |
| Cash From Financing | -$5M | -$5.1M | -$17.4M | -$826K | -$6.1M | |
| Free Cash Flow | -$208.4M | -$145.2M | $33.3M | -$257.8M | -$86.1M | |
CLOV
Sector
Market Cap
$1.9B
$34.5M
Price % of 52-Week High
77.41%
43.57%
Dividend Yield
0%
0%
Shareholder Yield
1.1%
-0.79%
1-Year Price Total Return
409.46%
-42.08%
Beta (5-Year)
--
0.660
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$3.43
200-day SMA
Buy
Level
$3.43
Bollinger Bands (100)
Buy
Level
3.29 - 4.23
Chaikin Money Flow
Sell
Level
-1.6B
20-day SMA
Buy
Level
$3.51
Relative Strength Index (RSI14)
Buy
Level
60.75
ADX Line
Buy
Level
29.68
Williams %R
Sell
Level
-19.697
50-day SMA
Buy
Level
$3.60
MACD (12, 26)
Sell
Level
-0.05
25-day Aroon Oscillator
Buy
Level
84
On Balance Volume
Sell
Level
-34.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.0275)
Buy
CA Score
(Annual)
Level (0.3159)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (2.6714)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.
Stock Forecast FAQ
In the current month, CLOV has received 2 Buy ratings 2 Hold ratings, and 0 Sell ratings. The CLOV average analyst price target in the past 3 months is $4.69.
-
Where Will Clover Health Investments Stock Be In 1 Year?
According to analysts, the consensus estimate is that Clover Health Investments share price will rise to $4.69 per share over the next 12 months.
-
What Do Analysts Say About Clover Health Investments?
Analysts are divided on their view about Clover Health Investments share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Clover Health Investments is a Sell and believe this share price will drop from its current level to $3.75.
-
What Is Clover Health Investments's Price Target?
The price target for Clover Health Investments over the next 1-year time period is forecast to be $4.69 according to 4 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is CLOV A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Clover Health Investments is a Leans Bullish. 2 of 4 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of CLOV?
You can purchase shares of Clover Health Investments via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Clover Health Investments shares.
-
What Is The Clover Health Investments Share Price Today?
Clover Health Investments was last trading at $3.85 per share. This represents the most recent stock quote for Clover Health Investments. Yesterday, Clover Health Investments closed at $3.77 per share.
-
How To Buy Clover Health Investments Stock Online?
In order to purchase Clover Health Investments stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
CVX Vs XOM Stock, Which Energy Play Is Best?
Chevron (NYSE:CVX) and Exxon Mobil (NYSE:XOM) are two of the…
Is it Safe to Invest in Google With OpenAI Threats?
For the last 20 years, Google parent company Alphabet (NASDAQ:GOOG,…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Buy
60
RGC alert for May 8
Regencell Bioscience Holdings [RGC] is up 17.9% over the past day.
Buy
92
TPB alert for May 8
Turning Point Brands [TPB] is down 7.37% over the past day.
Buy
74
LIVN alert for May 8
LivaNova PLC [LIVN] is up 1.22% over the past day.
